Related Experiment Video
Updated: Oct 2, 2025
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Measuring change in inclusion body myositis: clinical assessments versus imaging
Lindsay N Alfano1, Kendrea L Focht Garand2, Georgia A Malandraki3
1The Abigail Wexner Research Institute at Nationwide Children's Hospital, Center for Gene Therapy, Columbus, and the Department of Paediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. lindsay.alfano@nationwidechildrens.org.
Abstract:
Sporadic inclusion body myositis (sIBM) is a heterogeneous progressive inflammatory muscle disease impacting skeletal muscles in the head, neck, and limbs. Use of valid, reliable, sensitive, and standardised clinical and paraclinical outcome assessments (COA) are critical to inform both proactive clinical care and clinical trial design. Here we review clinical and imaging methods used to quantify muscle strength, size, or function in sIBM, and discuss their application to clinical practice and use in clinical trials. Considerations for future work to validate measures in this population are also discussed.
